53% of Israel’s 9.3M population has received both Pfizer doses
Infection rates, severe illness and hospitalisations dropping sharply
Of the few breakthrough infections (in immunised) proportionally more are the B.1.351 (first detected in South Africa) reut.rs/3mB02yc
Infection rates, severe illness and hospitalisations dropping sharply
Of the few breakthrough infections (in immunised) proportionally more are the B.1.351 (first detected in South Africa) reut.rs/3mB02yc
B.1.351 made up 1% of all the COVID19 cases studied, but in patients who had received two doses of the vaccine, the variant's prevalence rate was eight times higher than those unvaccinated - 5.4% versus 0.7%.
This suggests the vaccine may be less effective against the B.1.351 than B.1.1.7 (the dominant variant in Israel, see image)
This doesn’t mean ‘ineffective’
This doesn’t mean ‘ineffective’
The pre-print’s authors say
“Given the low frequency of B.1.351 across time, our results overall suggest that selection does not strongly favour the B.1.351 variant in the particular conditions in Israel”
medrxiv.org/content/10.110…
“Given the low frequency of B.1.351 across time, our results overall suggest that selection does not strongly favour the B.1.351 variant in the particular conditions in Israel”
medrxiv.org/content/10.110…
“In view of this low frequency of B.1.351 (across all groups of study herein...) ... it is possible that (a) vaccine effectiveness coupled with enacted non-pharmaceutical interventions remain sufficient to prevent its spread, and/or (b) B.1.1.7 outcompetes B.1.351”.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
